Prevalence and charactenistics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center

被引:67
作者
Maor, Yasmin [1 ]
Rahav, Galia [1 ]
Belausov, Natasha [1 ]
Ben-David, Debby [1 ]
Smollan, Gill [1 ]
Keller, Nathan [1 ]
机构
[1] Tel Aviv Univ, Chaim Sheba Med Ctr, Infect Dis Unit, Microbiol Lab, IL-52621 Tel Hashomer, Israel
关键词
D O I
10.1128/JCM.01262-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Infections with S. aureus with heterogeneous intermediate resistance to vancomycin (hVISA) are occurring more frequently. The detection of these infections, their prevalence, clinical characteristics, and significance are controversial. During 2003 and 2004, all blood culture isolates of methicillin-resistant Staphylococcus aureus (264 patients) at the Sheba Medical Center, Tel Hashomer, Israel, were assessed for hVISA by using the Etest macromethod. A total of 16 patients (6%) were positive for hVISA. Resistance to teicoplanin alone and to vancomycin alone using the Etest macromethod was found in 14 and 10 patients, respectively. Standard MICs to vancomycin were between 1 to 4 mg/ml. Most of these isolates (12 of 16 [75%]) would have been missed without specific testing. The median number of bacteremic days was 4. Seven patients had positive blood cultures for more than 5 days. Twelve patients died, and for eight of these the deaths were directly related to hVISA sepsis. We found that hVISA bacteremia was prevalent in our institution, and we suggest seeking hVISA in patients with persistent S. aureus bacteremia.
引用
收藏
页码:1511 / 1514
页数:4
相关论文
共 23 条
[1]   Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates [J].
Boyle-Vavra, S ;
Berke, SK ;
Lee, JC ;
Daum, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :272-277
[2]  
Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P322
[3]   Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene [J].
Chang, S ;
Sievert, DM ;
Hageman, JC ;
Boulton, ML ;
Tenover, FC ;
Downes, FP ;
Shah, S ;
Rudrik, JT ;
Pupp, GR ;
Brown, WJ ;
Cardo, D ;
Fridkin, SK .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1342-1347
[4]   Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus [J].
Charles, PGP ;
Ward, PB ;
Johnson, PDR ;
Howden, BP ;
Grayson, ML .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :448-451
[5]   Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia:: A meta-analysis [J].
Cosgrove, SE ;
Sakoulas, G ;
Perencevich, EN ;
Schwaber, MJ ;
Karchmer, AW ;
Carmeli, Y .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) :53-59
[6]   Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area [J].
Equía, JM ;
Liu, C ;
Moore, M ;
Wrone, EM ;
Pont, J ;
Gerberding, JL ;
Chambers, HF .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) :1617-1624
[7]  
Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542
[8]   A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital [J].
Garnier, F ;
Chainier, D ;
Walsh, T ;
Karlsson, A ;
Bolmström, A ;
Grelaud, C ;
Mounier, M ;
Denis, F ;
Ploy, MC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (01) :146-149
[9]  
Gerberding J, 1999, AM J INFECT CONTROL, V27, P520
[10]   Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin [J].
Hiramatsu, K ;
Aritaka, N ;
Hanaki, H ;
Kawasaki, S ;
Hosoda, Y ;
Hori, S ;
Fukuchi, Y ;
Kobayashi, I .
LANCET, 1997, 350 (9092) :1670-1673